St. Joseph’s Healthcare Establishes Centre for Psychedelic Research

A new research centre has been established at St. Joseph’s Healthcare Hamilton to explore the potential medical applications of psychedelics. The Centre for Health Innovation and Research in Psychedelics aims to generate comprehensive guidelines for the use of these substances in clinical settings. Dr. Anthony Adili, chief innovation officer at St. Joseph’s, emphasized the need for robust scientific evidence to support the administration of psychedelics, stating, “Psychedelics have shown great promise in some early studies. But promise alone is not enough.”

The initiative comes at a time when interest in psychedelic therapies is gaining momentum. According to a November news release from St. Joseph’s, the centre will connect researchers from across Canada and around the world, providing clinical space to treat and monitor patients undergoing psychedelic therapies. Although the centre aims for international collaboration, much of the initial research will take place at St. Joseph’s campus on West 5th Street.

Long-Term Commitment to Research

Dr. Adili, who also serves as vice chair of the department of surgery at McMaster University, expressed confidence in the centre’s future, indicating that it is expected to receive “long-standing funding” for “probably a couple decades.” The research will focus on various psychedelic substances, including psilocybin, LSD, MDMA, DMT, and ketamine, which have shown promise in treating conditions such as treatment-resistant depression, migraines, and anxiety. Currently, St. Joseph’s is conducting two trials: one examining psilocybin as a treatment for cannabis addiction and another focused on chronic pain management.

The acceptance of psychedelics as legitimate therapeutic interventions has significantly increased over the last decade. Yet, Dr. Adili cautioned that health professionals must differentiate “fact from fiction” and create actionable guidelines for usage.

Research Landscape and Challenges

In related developments, Dr. Ishrat Husain, a psychiatrist at the Centre for Addiction and Mental Health in Toronto, has been studying psychedelics since 2022, when he received Canada’s first federal grant for psilocybin research aimed at treatment-resistant depression. Despite this progress, Dr. Husain noted that he is not ready to prescribe psilocybin to patients. “I don’t think we have any reliable evidence to say that psilocybin therapy should be part of the treatment protocols at present,” he explained, highlighting the need for more extensive and robust trials.

While the excitement surrounding psychedelic therapy is palpable, Dr. Husain pointed out that current research is still in its infancy. He and his team recently excluded psychedelics from a set of international guidelines on depression due to insufficient data.

Looking ahead, Dr. Husain is optimistic about future studies, emphasizing the importance of collaborative efforts across multiple institutions. “The more institutions and the more regions of the country involved, the more generalizable and better the results will be,” he stated. This expanded research capacity will not only provide valuable insights but also increase patient access to emerging treatments through clinical trials. His team is working on a significant study with preliminary results anticipated in the first half of 2026, which could pave the way for clinical developments in psychedelic therapy.

As the landscape of mental health treatment evolves, the establishment of the Centre for Health Innovation and Research in Psychedelics at St. Joseph’s Healthcare represents a pivotal step forward in understanding and potentially harnessing the therapeutic benefits of psychedelics.